Circulating regulatory T cells (CD4+CD25+FOXP3+) decrease in breast cancer patients after vaccination with a modified MHC class II HER2/neu (AE37) peptide

Jeremy D. Gates, Guy T. Clifton, Linda C. Benavides, Alan K. Sears, Mark G. Carmichael, Matthew T. Hueman, Jarrod P. Holmes, Yusuf H. Jama, Mohamed Mursal, Athina Zacharia, Kathy Ciano, Steven Khoo, Alexander Stojadinovic, Sathibalan Ponniah, George E. Peoples

Research output: Contribution to journalArticlepeer-review

Abstract

Regulatory T cells (TReg), CD4+CD25+FOXP3+, are implicated in suppressing tumor immune responses. We analyzed peripheral blood lymphocytes (PBL) from breast cancer patients receiving a modified HLA class II HER2/neu peptide (AE37) vaccine for TReg cells and correlated their levels with vaccine-specific immune responses. The mean CD4+CD25+FOXP3+ TReg cells decreased in patients with vaccination with no significant difference in serum TGF-β levels. IFN-γ ELISPOT and DTH increased after vaccination with a good correlation between TReg cell reduction and size of DTH to AE37. The TReg cell reduction and associated immune response suggest that AE37 may be clinically useful.

Original languageEnglish (US)
Pages (from-to)7476-7482
Number of pages7
JournalVaccine
Volume28
Issue number47
DOIs
StatePublished - Nov 3 2010

Keywords

  • HER2/neu
  • Regulatory T cell
  • Vaccine

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Circulating regulatory T cells (CD4+CD25+FOXP3+) decrease in breast cancer patients after vaccination with a modified MHC class II HER2/neu (AE37) peptide'. Together they form a unique fingerprint.

Cite this